EMA updates on Cyberattack

18 January 2021
ema_big

The ongoing investigation of the cyberattack on the European Medicines Agency (EMA) revealed that some of the unlawfully accessed documents related to COVID-19 medicines and vaccines have been leaked on the internet.

This included internal/confidential email correspondence dating from November, relating to evaluation processes for COVID-19 vaccines. Some of the correspondence has been manipulated by the perpetrators prior to publication in a way which could undermine trust in vaccines.

Two EMA conditional marketing authorizations for COVID-19 vaccines were granted at the end of December/beginning of January following an independent scientific assessment. These approvals were for Pfizer (NYSE: PFE) and BioNTech’s (Nasdaq: BNTX) Comirnaty (BNT162b2) and Moderna’s (Nasdaq: MRNA) product, now called COVID-19 Vaccine Moderna and previously dubbed mRNA-1273.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical